Sarah Geers represents pharmaceutical and biotechnology clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the Patent Trial and Appeal Board (PTAB). Her practice spans Hatch-Waxman and other life science patent infringement actions, inter partes and post-grant review proceedings, and trade secret and misappropriation actions. Her litigation experience spans pre-suit preparation, discovery, trial, and appeal. Sarah is co-leader of Jones Day's PTAB area of focus.
Sarah recently achieved a victory on behalf of Merck in a bench trial of patent infringement actions against 16 generic defendants groups related to Bridion®, a first-in-class anesthesia reversal agent. She was also part of a team that helped Juno Therapeutics and Sloan Kettering win a more than $1.1 billion final award in a case in which the jury found that defendant Kite Pharma willfully infringed the asserted patent for cancer immunotherapy. Sarah has also been involved in the successful resolution of Hatch-Waxman litigation involving the transdermal patch Butrans®, as well as a plethora of patent infringement actions involving the pain medication OxyContin®.
Sarah is currently an adjunct professor at Seton Hall University School of Law, where she teaches a course on patent litigation.
Sarah was named a Law360 "Life Sciences Rising Star" in 2020. In 2023, she was named a "Next Generation Partner" in Patent Litigation by The Legal 500.
Before becoming a lawyer, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research.
Expérience
- Seton Hall University (J.D. summa cum laude 2010; Order of the Coif; Comments Editor, Law Review); University of Minnesota (B.S. in Chemistry with high distinction and B.A. in Spanish Studies with high distinction 2003; Tau Beta Pi)
- New York, New Jersey, and registered to practice before the U.S. Patent and Trademark Office
- Conversational Spanish
Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :
Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.